# Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

> **NCT06125951** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Actinogen Medical** · enrollment: 247 (actual)

## Conditions studied

- Dementia Moderate
- Dementia, Mild
- Alzheimer Disease

## Interventions

- **DRUG:** Xanamem
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06125951
- **Lead sponsor:** Actinogen Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2026-10
- **Final completion:** 2028-02
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125951, "Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06125951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*